Dexmedetomidine-associated abnormal blood pressure elevation
Conditions
Interventions
Hypertensive response group (HR):None
Non-hypertensive response group (NR):None
Sponsors
Luxian People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age 18–65 years; 2. ASA class I–II; 3. Scheduled for elective surgery with planned Dex administration before anesthesia induction; 4. Participants understand the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe cardiovascular diseases, hypertension (e.g., SBP =140 mmHg or DBP =90 mmHg, severe arrhythmia, heart failure, recent myocardial ischemia, etc.); 2. Severe hepatic or renal dysfunction (e.g., ALT/AST >2×ULN or significantly elevated creatinine, etc., as defined by the central standard); 3. Coagulation disorders or active bleeding risk; 4. Pregnancy or lactation; 5. Use of medications affecting autonomic nervous function or hemodynamic response within the past 2 weeks (ß-blockers, a-agonists/antagonists, etc.); 6. Allergy to Dex or related excipients; 7. Investigator deems the subject unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in systolic blood pressure (?SBP, mmHg); | — |
Secondary
| Measure | Time frame |
|---|---|
| Abnormal blood pressure elevation occurred (Yes/No);Differential expression profile from peripheral blood whole-transcriptome sequencing (DEGs/DERs).;Key pathway enrichment (KEGG/GSEA) and ceRNA network key nodes; | — |
Countries
China
Contacts
Public ContactHe Tianping
Luxian People's Hospital
Outcome results
None listed